Bio Path Number Of Shares Shorted vs. Debt To Equity

BPTHDelisted Stock  USD 0.19  0.01  5.00%   
Considering the key profitability indicators obtained from Bio Path's historical financial statements, Bio Path Holdings may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Bio Path's ability to earn profits and add value for shareholders.
For Bio Path profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bio Path to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bio Path Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bio Path's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bio Path Holdings over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bio Path Holdings Debt To Equity vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bio Path's current stock value. Our valuation model uses many indicators to compare Bio Path value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15CAPRCRNXACHVMBRXICVXAMTIBPTH 00.20.40.60.81.01.2 01M2M3M4M5M6M7M8M9M
Bio Path Holdings is rated below average in number of shares shorted category among its peers. It is rated below average in debt to equity category among its peers . The ratio of Number Of Shares Shorted to Debt To Equity for Bio Path Holdings is about  6,103,538 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bio Path by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bio Path's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Bio Debt To Equity vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Bio Path

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
79.35 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Bio Path

D/E

 = 

Total Debt

Total Equity

 = 
0.01 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Bio Debt To Equity Comparison

0.011.261.180.38100%
Bio Path is currently under evaluation in debt to equity category among its peers.

Bio Path Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bio Path, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bio Path will eventually generate negative long term returns. The profitability progress is the general direction of Bio Path's change in net profit over the period of time. It can combine multiple indicators of Bio Path, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Bio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bio Path. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bio Path position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bio Path's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Bio Path without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Dashboard Now

   

Portfolio Dashboard

Portfolio dashboard that provides centralized access to all your investments
All  Next Launch Module

Use Investing Themes to Complement your Bio Path position

In addition to having Bio Path in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Preferred Stock ETFs Thematic Idea Now

Preferred Stock ETFs
Preferred Stock ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Preferred Stock ETFs theme has 18 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Preferred Stock ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Bio OTC Stock

If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets